◀ Back to PPARA

PPARA — VCAM1

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: VCAM1 → PPARA (decreases)
  Evidence: PPARa activators prevent TNF-a?induced VCAM-1 expression in human saphenous vein endothelial cells, partly via inhibition of the NF-kB pathway.14

Text-mined interactions from Literome

Marx et al., Circulation 1999 (Arteriosclerosis) : PPARalpha activators inhibit cytokine induced vascular cell adhesion molecule-1 expression in human endothelial cells ... The present study investigated PPARalpha expression in human ECs and their regulation of vascular cell adhesion molecule-1 ( VCAM-1 ) ... Human ECs express PPARalpha , a potentially important regulator of atherogenesis through its transcriptional control of VCAM-1 gene expression
Jackson et al., Arterioscler Thromb Vasc Biol 1999 : We show that the PPAR activators 15-deoxy-Delta ( 12,14 ) -prostaglandin J ( 2 ) ( 15d-PGJ ( 2 ) ), Wyeth 14643, ciglitazone, and troglitazone, but not BRL 49653, partially inhibit the induced expression of vascular cell adhesion molecule-1 ( VCAM-1 ), as measured by ELISA, and monocyte binding to human aortic endothelial cells ( HAECs ) activated by phorbol 12-myristate 13-acetate ( PMA ) or lipopolysaccharide
Xu et al., Endocrinology 2001 : We therefore examined the effects of the PPARalpha activator fenofibrate and the GR activator dexamethasone on TNFalpha stimulated expression of IL-6 and vascular cell adhesion molecule-1 in vascular endothelial cells
Orasanu et al., J Am Coll Cardiol 2008 (Diabetes Mellitus, Type 2...) : Previously we reported PPARalpha but not PPARgamma agonists could repress VCAM-1 expression